Holen Sie sich die Stockscreener-App
1.37
4.18%
0.055
Schlusskurs vom Vortag:
$1.315
Offen:
$1.41
24-Stunden-Volumen:
236.38K
Relative Volume:
1.64
Marktkapitalisierung:
$6.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.04M
KGV:
-0.3129
EPS:
-4.3784
Netto-Cashflow:
$-6.17M
1W Leistung:
-25.14%
1M Leistung:
-19.41%
6M Leistung:
+37.01%
1J Leistung:
-44.53%
1-Tages-Spanne:
$1.20
$1.48
1-Wochen-Bereich:
$1.20
$1.9199
52-Wochen-Spanne:
$0.84
$2.68
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.37 | 8.83M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Form 8K Alzamend Neuro Inc For: 29 September By Investing.com - Investing.com Nigeria
Alzamend Neuro Highlights Early AL001 Brain Lithium Data - TipRanks
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - TipRanks
ALZN Q2 2026 Earnings: Wider-Than-Expected Loss for Pre-Revenue Biotech, Shares Still Edge HigherMargin Guidance - dars.gov.et
Alzamend Neuro regains Nasdaq listing compliance - Investing.com
Alzamend Neuro regains Nasdaq compliance - TradingView
Alzamend Neuro regains Nasdaq listing compliance By Investing.com - Investing.com UK
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - PR Newswire
Alzamend Neuro Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Alzamend Neuro Flags Substantial Going-Concern Doubt After Q1 Loss Widens - minichart.com.sg
Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary - TradingView
Alzamend Neuro (ALZN) raises cash but says conditions raise doubt it can keep operating - Stock Titan
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Shares DipCore Business Growth - dars.gov.et
ALZN Q1'26 Earnings: revenue estimate is 0 USD - tradingview.com
Alzamend Neuro Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Champions Oncology Inc. (CSBR) Peer Comparison – Compare with Others - Value Research
ALZN Q2 2026 Earnings: Narrower-than-Expected Net Loss Underscores Cost Discipline Amid Pipeline ProgressEstimate Revision Count - dars.gov.et
Alzamend Neuro (NASDAQ: ALZN) plans $25M preferred stock conversion vote - stocktitan.net
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Alzamend (ALZN) Results Versus Estimates: EPS Clears the Reported Estimate for the Current Session; Market Response: Shares Fall 4.29% in the Available RecordRevenue Guidance Range - vinanet.vn
IPO Databook: Alzamend Neuro (ALZN US)Aug 2026 - Smartkarma
Alzamend Neuro (ALZN) takes first step toward IPO with SEC filing - Stock Titan
Alzamend Neuro (ALZN) files amended insider trading report - Stock Titan
Alzamend’s lithium treatment data accepted for neuroscience meeting - Investing.com
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PR Newswire
Alzamend Neuro's AL001 fMRI abstract accepted for Neuroscience 2026 - scanx.trade
Alzamend (ALZN) Results Check: Reported EPS Tops Expectations for the Current Session; Market Reaction: Shares Move Higher 3.62% in the Current UpdateLong-Term Guidance - vinanet.vn
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Alzamend (ALZN) Results at a Glance: Profit Per Share Clears Its Benchmark on the Day; Post-Earnings Trading - vinanet.vn
Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com Canada
Alzamend to present lithium imaging data at Barcelona workshop - Investing.com South Africa
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - Investing News Network
Alzamend Neuro (ALZN) Advances 2.1% as Shares Hold Above $1.39 SupportDiagonal Spread Trade - vinanet.vn
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Remains CentralForward Guidance Trends - careplusvn.com
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com
Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks
Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.47 Highlights Cost DisciplineEarnings Call Q&A - dars.gov.et
ALZN|Alzamend Neuro Inc|Price:1.560|Chg%:-0.070 - TradingKey
Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView
TradingKey - TradingKey
Alzamend Neuro Inc (ALZN) Cash Flow - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro, Inc. Revenue Breakdown – NASDAQ:ALZN - TradingView
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALZN Q2 2026 Earnings: EPS Beat Surprises Market as Stock RalliesCapex Guidance - dars.gov.et
Alzamend Neuro Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Alzamend Neuro Announces Passing of Board Director - The Globe and Mail
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alzamend Neuro Inc-Aktie (ALZN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Apr 14 '26 |
Buy |
1.00 |
108,388 |
108,897 |
116,648 |
| AULT MILTON C III | Director |
Dec 23 '25 |
Sale |
2.07 |
1,851 |
3,825 |
0 |
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):